{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:00:11Z","timestamp":1791910811310,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Shanghai Municipal Commission of Health and Family Planning","award":["201440019"],"award-info":[{"award-number":["201440019"]}]},{"name":"The National Key Research and Development Program of China","award":["2016YFC0901504"],"award-info":[{"award-number":["2016YFC0901504"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870988"],"award-info":[{"award-number":["81870988"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jocn.2019.02.004","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T22:51:08Z","timestamp":1551480668000},"page":"160-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis"],"prefix":"10.1016","volume":"63","author":[{"given":"Liang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiansong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2019.02.004_b0005","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cca.2015.01.042","article-title":"An update on laboratory diagnosis in myasthenia gravis","volume":"444","author":"Oger","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jocn.2019.02.004_b0010","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14737175.2018.1491310","article-title":"Advances in autoimmune myasthenia gravis management","volume":"18","author":"Wang","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.jocn.2019.02.004_b0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2019.02.004_b0020","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2019.02.004_b0025","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jocn.2019.02.004_b0030","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/1756285615571873","article-title":"The emerging role of tacrolimus in myasthenia gravis","volume":"8","author":"Cruz","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jocn.2019.02.004_b0035","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/352803a0","article-title":"Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A","volume":"352","author":"Flanagan","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.jocn.2019.02.004_b0040","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/cei.12604","article-title":"Calcineurin inhibitors dampen humoral immunity by acting directly on naive B cells","volume":"180","author":"De Bruyne","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jocn.2019.02.004_b0045","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1016\/S0021-9258(18)53220-8","article-title":"Potentiation of glucocorticoid receptor-mediated gene expression by the immunophilin ligands FK506 and rapamycin","volume":"268","author":"Ning","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jocn.2019.02.004_b0050","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1212\/01.WNL.0000125254.99397.68","article-title":"Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis","volume":"62","author":"Takamori","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2019.02.004_b0055","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.clineuro.2004.07.013","article-title":"Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study","volume":"107","author":"Ponseti","year":"2005","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.jocn.2019.02.004_b0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jocn.2004.12.008","article-title":"Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone","volume":"13","author":"Shimojima","year":"2006","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jocn.2019.02.004_b0065","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1054\/jocn.2001.0907","article-title":"Low-dose tacrolimus for intractable myasthenia gravis","volume":"9","author":"Yoshikawa","year":"2002","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jocn.2019.02.004_b0070","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1756285617721092","article-title":"Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China","volume":"10","author":"Zhou","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jocn.2019.02.004_b0075","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s00415-017-8616-7","article-title":"Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis","volume":"264","author":"Wang","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2019.02.004_b0080","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2019.02.004_b0085","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2019.02.004_b0090","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","article-title":"Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis","volume":"64","author":"Ponseti","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2019.02.004_b0095","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1185\/030079906X104650","article-title":"Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis","volume":"22","author":"Ponseti","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jocn.2019.02.004_b0100","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.5114\/aoms.2013.39797","article-title":"FK506 attenuates thymic output in patients with myasthenia gravis","volume":"9","author":"Mitsui","year":"2013","journal-title":"Archives of Medical Science"},{"key":"10.1016\/j.jocn.2019.02.004_b0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/01.nrl.0000256352.77668.ef","article-title":"Beneficial effect of tacrolimus on myasthenia gravis with thymoma","volume":"13","author":"Mitsui","year":"2007","journal-title":"Neurologist"},{"key":"10.1016\/j.jocn.2019.02.004_b0110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10072-016-2769-5","article-title":"Long-term efficacy and side effects of low-dose tacrolimus for the treatment of Myasthenia Gravis","volume":"38","author":"Tao","year":"2017","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jocn.2019.02.004_b0115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jns.2017.05.060","article-title":"A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis","volume":"379","author":"Ahn","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2019.02.004_b0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4137\/JCM.S29601","article-title":"Treatment of myasthenia gravis in patients with elderly onset at advanced age","volume":"6","author":"Nishikawa","year":"2015","journal-title":"Jap Clin Med"},{"key":"10.1016\/j.jocn.2019.02.004_b0125","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000347068","article-title":"Tacrolimus monotherapy: a promising option for ocular myasthenia gravis","volume":"69","author":"Yagi","year":"2013","journal-title":"Eur Neurol"},{"key":"10.1016\/j.jocn.2019.02.004_b0130","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.intimp.2010.12.012","article-title":"Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis","volume":"11","author":"Zhao","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jocn.2019.02.004_b0135","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.21462","article-title":"Factors associated with response to calcineurin inhibitors in myasthenia gravis","volume":"41","author":"Nagane","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2019.02.004_b0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2007.12.008","article-title":"Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis","volume":"195","author":"Furukawa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2019.02.004_b0145","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jocn.2006.07.006","article-title":"The clinical significance of anti-heat shock cognate protein 71 antibody in myasthenia gravis","volume":"15","author":"Munakata","year":"2008","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jocn.2019.02.004_b0150","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2169\/internalmedicine.47.0513","article-title":"Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus","volume":"47","author":"Nagaishi","year":"2008","journal-title":"Int Med (Tokyo, Japan)"},{"key":"10.1016\/j.jocn.2019.02.004_b0155","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1248\/bpb.30.291","article-title":"P-glycoprotein function in peripheral blood mononuclear cells of myasthenia gravis patients treated with tacrolimus","volume":"30","author":"Tanaka","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jocn.2019.02.004_b0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2006.03.010","article-title":"Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis","volume":"247","author":"Tada","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2019.02.004_b0165","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","article-title":"Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)","volume":"76","author":"Konishi","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2019.02.004_b0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jns.2004.12.010","article-title":"Low-dose tacrolimus for two cases of myasthenia gravis with invasive thymoma that relapsed shortly after thymectomy","volume":"231","author":"Tsukaguchi","year":"2005","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2019.02.004_b0175","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1185\/030079904125004385","article-title":"Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis","volume":"20","author":"Kawaguchi","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jocn.2019.02.004_b0180","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/mus.10285","article-title":"Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells","volume":"27","author":"Utsugisawa","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2019.02.004_b0185","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0303-8467(03)00046-5","article-title":"Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis","volume":"106","author":"Wakata","year":"2003","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.jocn.2019.02.004_b0190","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/ncn3.12001","article-title":"Analysis of change in anti-acetylcholine receptor antibody and effect on myasthenia gravis symptoms by adjusting tacrolimus dosage according to the blood concentration","volume":"3","author":"Yokota","year":"2015","journal-title":"Neurol Clin Neurosci"},{"key":"10.1016\/j.jocn.2019.02.004_b0195","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro","volume":"40","author":"Kino","year":"1987","journal-title":"The Journal of Antibiotics"},{"key":"10.1016\/j.jocn.2019.02.004_b0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/jaut.1996.0111","article-title":"FK506 prevents induction of rat experimental autoimmune myasthenia gravis","volume":"10","author":"Yoshikawa","year":"1997","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jocn.2019.02.004_b0205","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2019.02.004_b0210","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2017.08.014","article-title":"Tacrolimus improves symptoms of children with myasthenia gravis refractory to prednisone","volume":"77","author":"Liu","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.jocn.2019.02.004_b0215","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.clinph.2012.01.017","article-title":"Early effect of tacrolimus in improving excitation-contraction coupling in myasthenia gravis","volume":"123","author":"Imai","year":"2012","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.jocn.2019.02.004_b0220","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clim.2007.10.001","article-title":"Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis","volume":"126","author":"Li","year":"2008","journal-title":"Clin Immunol (Orlando, Fla)"},{"key":"10.1016\/j.jocn.2019.02.004_b0225","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/cen3.12188","article-title":"Treatment of myasthenia gravis patients with calcineurin inhibitors in Japan: a retrospective analysis of outcomes","volume":"6","author":"Utsugisawa","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.1016\/j.jocn.2019.02.004_b0230","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/01.TP.0000137789.58694.B4","article-title":"Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients","volume":"78","author":"Tsuchiya","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.jocn.2019.02.004_b0235","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/ene.13652","article-title":"Dose optimization of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in patients with myasthenia gravis","volume":"25","author":"Chen","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2019.02.004_b0240","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ene.13189","article-title":"Adequate tacrolimus concentration for myasthenia gravis treatment","volume":"24","author":"Kanai","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2019.02.004_b0245","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/00007890-199506000-00018","article-title":"Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell","volume":"59","author":"Tamura","year":"1995","journal-title":"Transplantation"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586818316606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586818316606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:18:05Z","timestamp":1760822285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586818316606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":49,"alternative-id":["S0967586818316606"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2019.02.004","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2019.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}